Michael Higgins
Président chez VOYAGER THERAPEUTICS, INC.
Fortune : 316 438 $ au 31/05/2024
Profil
Michael J.
Higgins is currently the Chief Executive Officer & Director at KinDex Pharmaceuticals, Inc., Chairman at Voyager Therapeutics, Inc., and Chairman at Pulmatrix, Inc. He is also a Director at Morgan Stanley Private Equity Access Fund II LP, Sea Pharmaceuticals LLC, Madauder Therapeutics, Inc., Camp4 Therapeutics Corp., Cyclerion Therapeutics, Inc., and Nocion Therapeutics, Inc. Additionally, he serves as an Independent Director at Cyclerion Therapeutics, Inc. and Nocion Therapeutics, Inc. In the past, Mr. Higgins held positions as a Director at Pulmatrix Operating Co., Inc., Microbia, Inc., Genocea Biosciences, Inc., Ruthigen, Inc., and Ironwood Pharmaceuticals, Inc. He was also the VP-Corporate Finance & Business Development at Genzyme Corp.
and the Chief Operating Officer at Ironwood Pharmaceuticals, Inc. Furthermore, he served as the Chief Financial Officer at Procept, Inc. and the Boston Business Journal.
Mr. Higgins completed his undergraduate studies at Cornell University and earned an MBA from the Tuck School of Business at Dartmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/06/2024 | 31 314 ( 0,06% ) | 263 038 $ | 31/05/2024 | |
| 17/04/2024 | 20 000 ( 0,74% ) | 53 400 $ | 31/05/2024 | |
PULMATRIX INC
-.--% | 25/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Michael Higgins
| Sociétés | Poste | Début |
|---|---|---|
| PULMATRIX, INC. | Président | 21/04/2020 |
| VOYAGER THERAPEUTICS, INC. | Président | 13/06/2019 |
| CYCLERION THERAPEUTICS, INC. | Directeur/Membre du Conseil | 30/11/2023 |
Private Equity Access Fund II
 Private Equity Access Fund II Investment ManagersFinance Private Equity Access Fund II is private equity fund. | Directeur/Membre du Conseil | - |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 01/10/2017 |
Nocion Therapeutics, Inc.
 Nocion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nocion Therapeutics, Inc. is a biopharmaceutical company, which targets neurons mediating cough, itch, pain and inflammation without the addictive properties of opioids. The company was founded by Bruce Bean, Clifford Woolf and Bruce David Levy and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 01/09/2020 |
Madauder Therapeutics, Inc.
 Madauder Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Madauder Therapeutics, Inc. provides business services. The private company is based in Boston, MA. | Directeur/Membre du Conseil | 01/10/2016 |
| Morgan Stanley Private Equity Access Fund II LP | Directeur/Membre du Conseil | - |
Sea Pharmaceuticals LLC
 Sea Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Sea Pharmaceuticals LLC manufactures and markets pharmaceutical products and services. The company is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 01/01/2016 |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Michael Higgins
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Michael Higgins
| Cornell University | Undergraduate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| PULMATRIX, INC. | Health Technology |
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Ruthigen, Inc.
 Ruthigen, Inc. Pharmaceuticals: MajorHealth Technology Ruthigen, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade hypochlorous acid based therapeutics designed to prevent and treat infection in invasive applications. Its drug candidate, RUT58-60, is a broad spectrum anti-infective, which is developing for the prevention and treatment of infection in surgical and trauma procedures. The company was founded by Hojabr Alimi on January 18, 2013 and is headquartered in Santa Rosa, CA. | Health Technology |
KinDex Pharmaceuticals, Inc.
 KinDex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kindex Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing of novel therapeutics for the treatment of metabolic. The company is headquartered in Boston, MA. | Health Technology |
Procept, Inc.
 Procept, Inc. Pharmaceuticals: MajorHealth Technology Procept is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune disease, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis. The company is located in San Diego. CA | Health Technology |
Sea Pharmaceuticals LLC
Sea Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Sea Pharmaceuticals LLC manufactures and markets pharmaceutical products and services. The company is headquartered in Cambridge, MA. | Health Technology |
Microbia, Inc.
 Microbia, Inc. Pharmaceuticals: MajorHealth Technology Microbia, Inc. engages in the development of microbial manufacturing technologies for the production of chemicals from renewable raw materials. The company is headquartered in DE. | Health Technology |
| Morgan Stanley Private Equity Access Fund II LP | |
Madauder Therapeutics, Inc.
Madauder Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Madauder Therapeutics, Inc. provides business services. The private company is based in Boston, MA. | Commercial Services |
| Boston Business Journal | |
Nocion Therapeutics, Inc.
Nocion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nocion Therapeutics, Inc. is a biopharmaceutical company, which targets neurons mediating cough, itch, pain and inflammation without the addictive properties of opioids. The company was founded by Bruce Bean, Clifford Woolf and Bruce David Levy and is headquartered in Cambridge, MA. | Health Technology |
Pulmatrix Operating Co., Inc.
 Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Health Technology |
Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Private Equity Access Fund II
Private Equity Access Fund II Investment ManagersFinance Private Equity Access Fund II is private equity fund. | Finance |
